These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 14978141)

  • 21. Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: "natural suppressor" cells.
    Lan F; Zeng D; Higuchi M; Huie P; Higgins JP; Strober S
    J Immunol; 2001 Aug; 167(4):2087-96. PubMed ID: 11489992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The fate of donor T-cell receptor transgenic T cells with known host antigen specificity in a graft-versus-host disease model.
    Dey B; Yang YG; Preffer F; Shimizu A; Swenson K; Dombkowski D; Sykes M
    Transplantation; 1999 Jul; 68(1):141-9. PubMed ID: 10428282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease.
    Zeng D; Lewis D; Dejbakhsh-Jones S; Lan F; García-Ojeda M; Sibley R; Strober S
    J Exp Med; 1999 Apr; 189(7):1073-81. PubMed ID: 10190898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of protection from graft-versus-host disease mortality by IL-2. III. Early reductions in donor T cell subsets and expansion of a CD3+CD4-CD8- cell population.
    Abraham VS; Sachs DH; Sykes M
    J Immunol; 1992 Jun; 148(12):3746-52. PubMed ID: 1534824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation.
    Roback JD; Hossain MS; Lezhava L; Gorechlad JW; Alexander SA; Jaye DL; Mittelstaedt S; Talib S; Hearst JE; Hillyer CD; Waller EK
    J Immunol; 2003 Dec; 171(11):6023-31. PubMed ID: 14634114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delaying transplantation after total body irradiation is a simple and effective way to reduce acute graft-versus-host disease mortality after major H2 incompatible transplantation.
    Xun CQ; Tsuchida M; Thompson JS
    Transplantation; 1997 Jul; 64(2):297-302. PubMed ID: 9256191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation.
    Min CK; Maeda Y; Lowler K; Liu C; Clouthier S; Lofthus D; Weisiger E; Ferrara JL; Reddy P
    Blood; 2004 Nov; 104(10):3393-9. PubMed ID: 15280194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo administration of interleukin-6 in murine allogeneic bone marrow chimeras: early and delayed enhancement of hematopoiesis accompanied with split tolerance but not with graft-versus-host disease.
    Imamura M; Hashino S; Kobayashi H; Tanaka J; Imai K; Han M; Fujii Y; Kobayashi M; Higa T; Kasai M
    Immunobiology; 1994 Jun; 190(4-5):346-67. PubMed ID: 7982720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
    Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JL
    J Clin Invest; 1999 Aug; 104(4):459-67. PubMed ID: 10449438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
    Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fas-deficient lpr mice are more susceptible to graft-versus-host disease.
    van Den Brink MR; Moore E; Horndasch KJ; Crawford JM; Hoffman J; Murphy GF; Burakoff SJ
    J Immunol; 2000 Jan; 164(1):469-80. PubMed ID: 10605044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC; Friedman TM; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J-->C57BL/6J x bm12)F1 mice.
    Brown GR; Lee E; Thiele DL
    J Immunol; 2002 Mar; 168(6):3065-71. PubMed ID: 11884480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Massive activation-induced cell death of alloreactive T cells with apoptosis of bystander postthymic T cells prevents immune reconstitution in mice with graft-versus-host disease.
    Brochu S; Rioux-Massé B; Roy J; Roy DC; Perreault C
    Blood; 1999 Jul; 94(2):390-400. PubMed ID: 10397705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.
    Murphy WJ; Welniak LA; Taub DD; Wiltrout RH; Taylor PA; Vallera DA; Kopf M; Young H; Longo DL; Blazar BR
    J Clin Invest; 1998 Nov; 102(9):1742-8. PubMed ID: 9802888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Production of donor T cells is critical for induction of donor-specific tolerance and maintenance of chimerism.
    Xu H; Chilton PM; Huang Y; Schanie CL; Ildstad ST
    J Immunol; 2004 Feb; 172(3):1463-71. PubMed ID: 14734723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intermediate TCR cells can induce graft-versus-host disease after allogeneic bone marrow transplantation.
    Weerasinghe A; Kawamura T; Moroda T; Seki S; Watanabe H; Abo T
    Cell Immunol; 1998 Apr; 185(1):14-29. PubMed ID: 9636679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone Marrow Graft-Versus-Host Disease in Major Histocompatibility Complex-Matched Murine Reduced-Intensity Allogeneic Hemopoietic Cell Transplantation.
    Shahin K; Mattar Z; Silveira P; Hsu WH; Bendall L; Hart D; Bradstock KF
    Transplantation; 2017 Nov; 101(11):2695-2704. PubMed ID: 28319565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.